Articles by tag: crispr

CRISPR vision restoration: FDA approval for testing

A US startup received FDA approval to test CRISPR therapy for people born blind with Leber congenital amaurosis. Details, risks, and prospects in the article.

CRISPR Therapy HAE: Phase 3 Data from Intellia at EAACI 2026

Intellia presented the long-awaited results of phase 3 of CRISPR therapy lonvoguran ziclumeran for hereditary angioedema. Reduction of attacks by 87%, 62% of patients without therapy. Learn more.

Gene vgll3: mechanism of aging and cancer | Nature Communications

Discovery of the vgll3 gene confirms the theory of antagonistic pleiotropy: accelerated growth leads to aging and cancer. Learn about the implications for longevity research.

Breakthrough Prize 2026 Laureates: Gene Therapy and CRISPR

Analysis of Breakthrough Prize 2026 Laureates: How FDA-Approved Gene Therapy and CRISPR Editing Became a New Business Model and What Awaits ALS Therapy. Learn About the Main Trends.

evoCAST: gene insertion without DNA cuts — breakthrough 2026

The new evoCAST tool inserts whole genes without double-strand breaks. Efficiency increased 400-fold. Learn how this will change gene therapy.

Personalized CRISPR therapy saved an infant: in vivo breakthrough

A child with the ultra-rare CPS1 mutation survived thanks to personalized CRISPR therapy in 6 months. Learn about the breakthrough in genetic engineering and N-of-1 platforms.

CRISPR stem cells against blood cancer: breakthrough or failure

Analysis of a clinical trial: how edited stem cells are changing therapy for acute myeloid leukemia. Learn about hidden risks and the economics of the method.

Nanotechnology against cancer chemoresistance: a review from EUR J CANCER

Breakthrough in oncology: how nanoparticles and CRISPR epigenome editing reverse tumor resistance to chemotherapy. Learn about clinical successes in 2026.

In vivo gene editing: CRISPR therapy for hereditary angioedema

Single-dose CRISPR therapy NTLA-2002 reduced hereditary angioedema attacks by 87% in phase III. Learn how this will change treatment and pave the way to a cure.

In vivo gene editing: phase 3 of HAE therapy successful

First ever successful phase 3 in vivo gene editing: lonvo-z therapy reduces HAE attacks by 87%. Learn about the breakthrough and discontinuation of prophylaxis.